Novartis's atrasentan Phase III results show a 36.1% reduction in proteinuria in the ALIGN study for IgA nephropathy, a rare kidney disease.
Novartis atrasentan Phase III results demonstrate a 36.1% reduction in proteinuria (protein in urine) in the ALIGN study, versus placebo+supportive care. This further strengthens Novartis's IgA nephropathy (IgAN) portfolio and shows potential to reduce persistent proteinuria and preserve kidney function. IgAN is a progressive, rare kidney disease with a need for effective, targeted therapies.
May 25, 2024
3 Articles